Research on the effect of Compound Embryonic Bovine Liver Extract Tablets on patients with type 2 diabetes and nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000404

Enrollment

Unknown

Registered

2009-05-19

Start date

2009-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus companied with nonalcoholic fatty liver disease

Interventions

Group B:Continue the previous treatment

Group A:Compound Embryonic Bovine Liver Extract Tablets, 2# tid, the previous treatment not changed.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. to be the T2DM; 2. to be treated without insulin, not changed for over 1 month; 3. to be fatty liver according to ultrasound.

Exclusion criteria

Exclusion criteria: 1. alcohol intake>140g per week for male, >70g per week for female; 2. with other deseases resulting in fatty liver, such as virus hepatitis, drug-induced liver disease, total parenteral alimentation and Wilson's disease; 3. treament of weight-reducing drug, antioxidant and hepatinica in the past 1 month; 4. kidney dysfunction; 5. coronary artery disease, acute or chronic heart dysfunction; 6. pregnant or lactation women; 7. acute infectious diseases, operation or under other stress condition.

Design outcomes

Primary

Measure	Time frame
improvement of fatty liver;	—

Secondary

Measure	Time frame
improvement of insulin resistance;	—

Countries

China

Contacts

Public ContactLi Yan

hfxyl@163.net+86 0 13719165213

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026